This goal of this Phase 1 clinical trial is to test how safe and effective belantamab mafodotin is when combined with bortezomib, lenalidomide, and dexamethasone. Researchers want to determine the safest and most effective dose of belantamab mafodotin, and study whether it can improve your myeloma when combined with the other study drugs.
This trial is currently open and accepting patients.
This trial is seeking approximately 144 patients. Patients will receive the study drugs over 21 or 28 day cycles and can continue to receive the study drugs as long as they are benefitting from them, don’t develop bad side effects, and their myeloma does not get worse.
While participating in this trial patients will need to have additional eye exams and screenings and are not allowed to wear contact lenses (except for bandage contact lenses if indicated). Patients will need to give themselves eye drops (artificial tears) each day as long as they are receiving belantamab mafodotin.
This trial will look at how patients react to and how the body uses belantamab mafodotin at different doses when taken together with bortezomib, lenalidomide and dexamethasone. We also want to know how the combination of these drugs affects your cancer. We will give patients in the trial different doses of belantamab mafodotin. The other three drugs will be given at the doses allowed in the country where you are located. The effects of the study drugs, both good and bad, will be studied.
There may be up to eight planned dose levels of belantamab mafodotin.
If you have stopped study treatment and your multiple myeloma has not gotten worse, you will have one further follow up visit and will then stop the trial and receive another treatment prescribed by your study doctor. You may choose to stop participating in this trial at any time. If your myeloma gets worse, or you develop bad side effects, researchers may remove you from the trial.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Enrollment: 144 patients (estimated)View More
Read the latest news and updates on this trial.
July 14, 2020
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to 0 in favor of approving belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have previously received at least 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and a CD38-directed antibody.
View all clinical trial locations sorted by state.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message